GARNET: high SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection [abstract 163]

Welzel TM, Zeuzem S, Dumas EO, et al. GARNET: high SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection [abstract 163]. New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016. Paris, France; 2016.

Publication Type:

Conference Proceedings

Authors:

T M Welzel; Stefan Zeuzem; Dumas, EO.; et, al

Source:

New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016, Number 163, Paris, France (2016)

Abstract:

Abstact 163

Cited On:

Export Citation:
RIS Format
Top